The 3-month PDUFA extension is a modest negative for near-term sentiment, but the absence of safety or manufacturing issues limits downside. Traders should watch for any FDA advisory committee announcement or additional data requests ahead of the new December 27, 2026 PDUFA date. The stock may trade on pipeline sentiment until the new decision date.
PRAX drugs
PRAX drug pipeline →- ▲ relutrigine 8/10 Filed/PDUFA (NDA under priority review) · PDUFA date Dec 27, 2026
- ▲ ulixacaltamide 8/10 Filed/NDA under FDA review (PDUFA January 29, 2027) · PDUFA date Jan 29, 2027
- ● vormatrigine 5/10 Phase 3
- ◆ elsunersen 4/10 Phase 2/3 (registrational)
- ● PRAX-110 4/10
- 4 more · All PRAX drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $334.79entry
- T+1 · 5mo ago −4.54%α −4.40% · $319.60
- T+5 · 4mo ago −6.36%α −6.96% · $313.50
- T+20 · 4mo ago −5.67%α −4.64% · $315.80
- T+60 · 8w ago −15.73%α −18.55% · $282.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Praxis Precision Medicines announced a 3-month FDA extension of the PDUFA target action date for its relutrigine NDA (SCN2A/SCN8A DEEs) from September 27, 2026 to December 27, 2026, following the submission of additional sensitivity analyses deemed a major amendment. No new clinical studies were requested and no safety or manufacturing concerns were cited, but the delay introduces near-term uncertainty for the company's lead pipeline asset.
Key Facts
- FDA extended PDUFA target action date for relutrigine NDA by 3 months to December 27, 2026
- Extension triggered by submission of additional sensitivity analyses of existing clinical data, classified as a major amendment
- No new clinical studies were requested and no safety or manufacturing concerns were cited
- Review remains active and ongoing; company continues preparations for launch
Financial Impact
Delay of potential first commercial revenue by at least 3 months; no financial figures disclosed in filing
Risk Factors
- Potential for further FDA delays or a complete response letter at the new PDUFA date
- Competitive developments in DEE treatment landscape could erode market opportunity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001689548-26-000069 |
| Document: 0001689548-26-000069-index-headers.html | 0001689548-26-000069 |
| Document: 0001689548-26-000069-index.html | 0001689548-26-000069 |
| Document: 0001689548-26-000069.txt | 0001689548-26-000069 |
Track record
16 reports on PRAX
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +8.87% at T+20 after the Apr 6, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
- Jun 29, 202620w ago 8-K Bearish 6/10 Viewing Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
- Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
- May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers